Actinium Pharmaceuticals, Inc.
ATNMDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Iomab-B | Phase 3 | Acute Myeloid Leukemia | - | - |
Cytarabine (Phase 1 only) | Phase 2 | AML | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Actinium Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Actinium Pharmaceuticals, Inc.'s (ATNM) pipeline across Phase 3, Phase 2. Its lead program is Iomab-B (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Actinium Pharmaceuticals, Inc.'s next FDA catalyst?→
Actinium Pharmaceuticals, Inc.'s (ATNM) next tracked catalyst is a Earnings expected November 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ATNM biotech catalysts?→
Add ATNM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Actinium Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.